223 related articles for article (PubMed ID: 34159471)
1. Association of histological subtype with risk of recurrence in craniopharyngioma patients: a systematic review and meta-analysis.
Wu J; Wu X; Yang YQ; Ding H; Yang L; Bao YY; Zhou L; Yang CX; Hong T
Neurosurg Rev; 2022 Feb; 45(1):139-150. PubMed ID: 34159471
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and factors influencing hypothalamic pituitary dysfunction in patients with craniopharyngioma.
Guo Y; Pei L; Li Y; Li C; Gui S; Ni M; Liu P; Zhang Y; Zhong L
Front Endocrinol (Lausanne); 2023; 14():1180591. PubMed ID: 37324266
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Endocrine and Metabolic Comorbidities in a National Cohort of Patients with Craniopharyngioma.
Jazbinšek S; Kolenc D; Bošnjak R; Faganel Kotnik B; Zadravec Zaletel L; Jenko Bizjan B; Vipotnik Vesnaver T; Battelino T; Janež A; Jensterle M; Kotnik P
Horm Res Paediatr; 2020; 93(1):46-57. PubMed ID: 32460296
[TBL] [Abstract][Full Text] [Related]
4. Comparison of central diabetes insipidus (antidiuretic hormone deficiency) and stalk effect in patients with adamantinomatous and papillary craniopharyngioma.
Feng Y; Zhong L
Acta Neurol Belg; 2024 Apr; ():. PubMed ID: 38669000
[TBL] [Abstract][Full Text] [Related]
5. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neuroendocrine dysfunction in patients with adamantinomatous and papillary craniopharyngiomas.
Feng Y; Ni M; Wang YG; Zhong LY
Exp Ther Med; 2019 Jan; 17(1):51-56. PubMed ID: 30651764
[TBL] [Abstract][Full Text] [Related]
7. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
[TBL] [Abstract][Full Text] [Related]
9. Association of pituitary stalk management with endocrine outcomes and recurrence in microsurgery of craniopharyngiomas: A meta-analysis.
Li K; Lu X; Yang N; Zheng J; Huang B; Li L
Clin Neurol Neurosurg; 2015 Sep; 136():20-4. PubMed ID: 26056807
[TBL] [Abstract][Full Text] [Related]
10. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome.
Weiner HL; Wisoff JH; Rosenberg ME; Kupersmith MJ; Cohen H; Zagzag D; Shiminski-Maher T; Flamm ES; Epstein FJ; Miller DC
Neurosurgery; 1994 Dec; 35(6):1001-10; discussion 1010-1. PubMed ID: 7885544
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of preoperative inflammatory markers in craniopharyngioma: a multicenter cohort study.
Chen M; Zheng SH; Yang M; Chen ZH; Li ST
J Neurooncol; 2018 May; 138(1):113-122. PubMed ID: 29388032
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
[TBL] [Abstract][Full Text] [Related]
13. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
14. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
15. Ectopic recurrence of craniopharyngioma in the posterior fossa: Case report and review of the literature.
Selfa A; Arráez C; Ros Á; Linares J; Cerro L; Arráez MÁ
Neurocirugia (Astur : Engl Ed); 2023; 34(1):32-39. PubMed ID: 36623891
[TBL] [Abstract][Full Text] [Related]
16. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
Esheba GE; Hassan AA
J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
[TBL] [Abstract][Full Text] [Related]
17. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
[TBL] [Abstract][Full Text] [Related]
18. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.
Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101
[TBL] [Abstract][Full Text] [Related]
19. Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis.
Alotaibi NM; Noormohamed N; Cote DJ; Alharthi S; Doucette J; Zaidi HA; Mekary RA; Smith TR
World Neurosurg; 2018 Jan; 109():487-496.e1. PubMed ID: 28987837
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Features of Craniopharyngioma: A 15-Year Study From a Tertiary Care Center in Pakistan.
Haroon S; Afzal A; Zia S; Ali SJ; Zia F; Shamail F; Irfan M; Hashmi AA
Cureus; 2021 Mar; 13(3):e14153. PubMed ID: 33936868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
